.png)
PermeAct™ Delivery Tech — advanced technology for enhanced ingredient delivery & bioavailability
PermeAct™ Delivery Tech also know as ALM Delivery Technology is a unique and proprietary delivery technology shown to enhance active ingredient uptake and bioavailability, regardless of particle size.
Produced using a highly specific and proprietary process, it not only helps amplify the absorption and bio-availability of ingredients, but also provides a direct benefit to cellular physiology.
Effects can be made more or less assertive as desired (to keep active compounds local or create a more systemic effect).
The self-contained delivery system creates a phenomenon akin to electroporation, in which electrostatic repulsion creates short-lived electric voltage pulses. This opens ionic channels on physiologic tissue allowing delivery of constituents, either topically of orally.
PermeAct™ Delivery Tech has been evaluated in human skin tissue cultures, animal testing (non-cruel), and human studies including double-blind placebo-controlled studies. The technology has been demonstrated to be capable of creating physiological responses with compounds that would normally be unable to penetrate tissue membranes, creating both profound local and/or definitive systemic benefits.
A number of articles have appeared in peer reviewed journals featuring proprietary formulations combined with differing iterations of the PermeAct™ Delivery Tech. Some of the better-known publications include The Journal of The Royal Society of Chemistry, The Journal of FASEB (Federation of American Societies of Experimental Biology, The American Journal of Clinical Nutrition, The Journal of Addiction Research & Therapy, and The American Journal of Biomedical Science & Research.
Summary of Clinical Work, Published Articles, and Formal Presentations For Various Formulas (oral and topical) all utilizing ALM Delivery Technology.
Changing Body Composition with A Transcutaneous Serum: Biometric and Lipid Panel Analysis Copyright © Diane Irvine Duncan This work is licensed under Creative Commons Attribution 4.0 License AJBSR.MS.ID.002627 American Journal of Biomedical Science & Research www.biomedgrid.com ALM DT used exclusively by license for topical compound for clinical study.
Formal Presentation Made At:
American Society of Aesthetic and Plastic Surgeons-Vancouver (May, 2024 International Society of Aesthetic and Plastic Surgeons-Cartegena (June, 2024).
Finished in top 3 places for best new treatment in category of treatment/procedure in the Wellness/Integrative Medicine category at the World Medical Congress of Anti-Aging-Monte Carlo (March 2024).
B.S. Morrison, S. Hesson. Effective body recomposition vs. misconceptions of the traditional weight loss strategies: TRCAP21 - a novel technological breakthrough in body recomposition. Functional Foods in Health and Disease 2022; 12(4): 134-150. doi: https://www.doi.org/10.31989/ffhd.v12i3.905.
D. Bagchi, B.W. Downs, M. Bagchi, S. Kushner. A technological breakthrough in developing a stateof-the-art nutraceutical sports nutrition formulation to enhance vitality, mental acuity, vigilance, energy, and stamina. Food Prod Process and Nutr 2022; 4, 6 https://doi.org/10.1186/s43014-022- 00085-1.
Featured in Royal Society of Chemistry
D. Bagchi, B.W. Downs, M. Bagchi, S.P. Banik, S. Kushner, B. Morrison, S. Chakraborty, S. Hesson. Phytoceutical based traditional weight loss strategies for management of body recomposition: Common misconceptions and novel technological breakthroughs. In: Dietary Supplements with Antioxidant Activity - understanding mechanisms and potential health benefits (Editors: C. Alasalver, F. Shahidi, & C.T. Ho Eds.). 2021, Royal Society of Chemistry, UK.
B.W. Downs, J.R. Corbier, N. Speight, S. Kushner, T. Aloisio, M. Bagchi, D. Bagchi. Anemia: Influence of Dietary Fat, Sugar, and Salt on Hemoglobin and Blood Health. In: Dietary Sugar, Salt, and Fat in Human Health. Editors: H.G. Preuss, D. Bagchi. Elsevier/ Academic Press, Amsterdam, Boston, USA, 2020, pp. 103-128.
K. Blum, B.W. Downs, M. Bagchi, S. Kushner, B.S. Morrison, J. Galvin, K. Randsdorp, J. Randsdorp, R.D. Bagdaiyan, D. Bagchi. Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multinutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation. Journal of Systems and Integrative Neuroscience. J Syst Integr Neurosci. 2020 Jun 29;7:10.15761/JSIN.1000234. doi: 10.15761/JSIN.1000234.
B.W. Downs, S.P. Banik, M. Bagchi, B.S. Morrison, S. Kushner, M. Piacentino, D. Bagchi. Design of a novel bioflavonoid and phytonutrient enriched formulation in boosting immune competence and sports performance: A Product Development Investigation. Am. J. Biopharm. Pharm. Sci. 2021:1;2 doi: 10.25259/AJBPS_2_2021.
EXPERIMENTAL BIOLOGY 2021 ABSTRACT CONFIRMATION OF POSTER PRESENTATION – ASBMB/Biochemistry and Molecular Biology April 27-30, 2021, virtual presentation A Novel Prodosomed PL425 PEC Phytoceutical-Fortified Electrolyte Formulation, PerformLyte, Boosts Cellular Energy, Metabolic Homeostasis, and Neuromuscular Synergy in Trained Athletes.
Publication in Peer-Reviewed Journal
The effect of VMP35 supplement ingredients encapsulated in a novel Phospholipid Prodosome SK713 SLP nutrient delivery technology on properties of live human blood. Kenneth Blum, B. William Downs, Steven Kushner, Ted Aloisio, Frans J. Cronjé FFHD: Online ISSN: 2160-3855 Functional Foods in Health & Disease Vol 5, No 9 (2015).
Publication in Peer-Reviewed Journal
Declinol, a Complex Containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, Significantly Reduced Alcohol Use Disorders Identification Test (AUDIT) Scores in Moderate to Heavy Drinkers: A Pilot Study. J Addict Res Ther 4:153.
Publication in Peer-Reviewed Journal
Safety and efficacy of a novel KD120 MEC multi-enzyme complex (N-Sorb®) in human volunteers B. William Downs, Steve Kushner, Manashi Bagchi, Anand Swaroop and Debasis Bagchi, April 2017 The FASEB Journal, vol. 31 no. 1 Supplement lb312.
Formal Poster Presentation at Harvard School of Medicine
Safety and efficacy of a novel KD120 MEC multi-enzyme complex (N-Sorb®) in human volunteers Berrnard W Downs, Steve M Kushner, Manashi Bagchi, Anand Swaroop and Debasis Bagchi, 22nd International Conference “Functional Foods and Chronic Diseases in Health: Science and Practice” Harvard Medical School, Boston, MA, USA on September 22-23.
Publication in Peer-Reviewed Journal
Safety and Efficacy of N-SORB® a Proprietary KD120 MEC Metabolically Activated Enzyme Formulation: A Randomized, Double-Blind, Placebo-Controlled Study Journal of the American College of Nutrition - ID UACN-2019-0023.R1 Manashi Bagchi, Jean-Ronel Corbier, Berrnard William Downs, Steve W Kushner, Ted Aloisio.
Publication in Peer-Reviewed Journal
VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis. Corbier JR, Downs BW, Kushner S, Aloisio T, Bagchi D, Bagchi M. Food and Nutrition Research. 2019 May 9;63.3-12-20.
Featured in Chapter of Textbook for Advanced Studies
Metal Toxicology Encyclopedia (CRC Press/Taylor Francis Publishing)Development and Utilization of a Novel Prodosomed Electrolyte and Phytochemical Formulation Technology to Restore Metabolic Homeostasis (Chapter 5).
Additional Clinical Studies
Safety and Efficacy of a topical POS-720 trans-dermal serum. Rejuvenation of female sexual function by enhancing localized blood flow-A double-blind placebo-controlled single crossover study utilizing ultrasound doppler measurement. Red Alinsod, M.D. FACOG, FACS, ACGE, Kushner, S., Richard M. Goldfarb, M.D., FACS, Peter Sinaiko, M.D., AUA.
Alyveᴿˣ has been involved in the weight loss and peptide industry for years and are the creators of the PermeAct™ Delivery Technology. They identified a major gap in the market — many patients who could benefit from life-changing medications were held back by a fear of needles, leaving them without access to effective treatment. Alyveᴿˣ solved this problem by developing sublingual and transdermal delivery methods, making these medications accessible to everyone.
No, you don’t need insurance to make treatment accessible! Our care model is designed to make access straightforward and affordable without requiring coverage.
Our network of partner physicians may prescribe FDA-approved and compounded medications. Other offerings may include peptide therapies and medications that support metabolism, recovery, or performance; based on clinical suitability and your health goals. Note: Compounded medications are prepared based on specific patient needs and are not reviewed or approved by the FDA for safety or effectiveness. Prescription required. Results may vary.
PermeAct™ delivery technology is different from other delivery technologies in several ways. It has been clinically researched and validated in several different formats and also been featured in various clinical studies in finished formulations that have resulted in publications in scientific journals. The delivery technology is capable of use in both topical and oral products and consist of all GRAS ingredients making it safe for use in any format. To date, we have not found any compound of any particle size that we cannot deliver through physiological tissue to create a positive effect both locally and systemically. The PermeAct™ technology does not affect the compound or carrier vehicle. Instead, it reacts with surface tissue that allows for both sublingual and transdermal permeation.
PermeAct™ Delivery Tech also know as ALM Delivery Technology is a unique and proprietary delivery technology shown to enhance active ingredient uptake and bioavailability, regardless of particle size.
Produced using a highly specific and proprietary process, it not only helps amplify the absorption and bio-availability of ingredients, but also provides a direct benefit to cellular physiology.
Effects can be made more or less assertive as desired (to keep active compounds local or create a more systemic effect).
The self-contained delivery system creates a phenomenon akin to electroporation, in which electrostatic repulsion creates short-lived electric voltage pulses. This opens ionic channels on physiologic tissue allowing delivery of constituents, either topically of orally.
PermeAct™ Delivery Tech has been evaluated in human skin tissue cultures, animal testing (non-cruel), and human studies including double-blind placebo-controlled studies. The technology has been demonstrated to be capable of creating physiological responses with compounds that would normally be unable to penetrate tissue membranes, creating both profound local and/or definitive systemic benefits.
A number of articles have appeared in peer reviewed journals featuring proprietary formulations combined with differing iterations of the PermeAct™ Delivery Tech. Some of the better-known publications include The Journal of The Royal Society of Chemistry, The Journal of FASEB (Federation of American Societies of Experimental Biology), The American Journal of Clinical Nutrition, The Journal of Addiction Research & Therapy, and The American Journal of Biomedical Science & Research.